One Company That's Set to Win From Precision Medicine
In the last few decades, incredible strides have been made in genome typing and precision medicine technology. What used to cost hundreds of thousands of dollars is now available for $100, opening up the biotech world to tons of new research and treatment opportunities. But the vast majority of clinical trials fail, and biotechs are very risky investments.
In this clip from Industry Focus: Healthcare, host Kristine Harjes and contributor Todd Campbell explain why most of the precision medicine space is risky for investors, and how Illumina (NASDAQ: ILMN) is one company that gets exposure to the industry without taking on that astronomically high failure risk.
A full transcript follows the video.
Source: Fool.com
Illumina Inc. Stock
€110.94
3.510%
The stock is one of the favorites of our community with 27 Buy predictions and 4 Sell predictions.
As a result the target price of 162 € shows a positive potential of 46.02% compared to the current price of 110.94 € for Illumina Inc..
